ALEC
Alector, Inc.
Price Chart
Latest Quote
$1.99
Current Price| Previous Close | $1.89 |
| Open | $1.87 |
| Day High | $2.03 |
| Day Low | $1.84 |
| Volume | 846,733 |
Stock Information
| Shares Outstanding | 109.15M |
| Total Debt | $37.88M |
| Cash Equivalents | $291.11M |
| Revenue | $69.05M |
| Net Income | $-107.74M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $217.21M |
| EPS (TTM) | $-1.06 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 13/42| Debt to Equity | 0.34 |
| Debt to Earnings | -0.36 |
| Current Ratio | 3.40 |
| Quick Ratio | 3.31 |
| Avg Revenue Growth | -12.86% |
| Profit Margin | -118.39% |
| Return on Equity | -93.89% |
| Avg FCF Growth | -44.57% |
| FCF Yield | -106.42% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $1.99 | 851,200 |
| 2026-01-30 | $1.89 | 1,204,500 |
| 2026-01-29 | $1.91 | 469,500 |
| 2026-01-28 | $1.91 | 778,000 |
| 2026-01-27 | $1.95 | 226,800 |
| 2026-01-26 | $1.93 | 773,900 |
| 2026-01-23 | $1.94 | 671,900 |
| 2026-01-22 | $1.92 | 516,900 |
| 2026-01-21 | $1.92 | 691,500 |
| 2026-01-20 | $1.83 | 1,181,400 |
| 2026-01-16 | $1.84 | 1,207,200 |
| 2026-01-15 | $1.82 | 2,106,000 |
| 2026-01-14 | $1.85 | 1,286,900 |
| 2026-01-13 | $1.92 | 739,000 |
| 2026-01-12 | $1.84 | 1,271,900 |
| 2026-01-09 | $1.86 | 1,330,000 |
| 2026-01-08 | $1.77 | 1,001,900 |
| 2026-01-07 | $1.76 | 1,259,300 |
| 2026-01-06 | $1.69 | 1,421,100 |
| 2026-01-05 | $1.60 | 1,368,900 |
About Alector, Inc.
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
📰 Latest News
Looking At The Narrative For Alector (ALEC) After Latozinemab Setback And Cost Cuts
Simply Wall St. • 2026-01-20T00:11:01Z
How the Narrative Surrounding Alector Has Changed After the Latozinemab Trial Failure
Simply Wall St. • 2025-12-05T21:08:34Z
How Analysts See Alector’s Story Shifting After the Latest Clinical Setback
Simply Wall St. • 2025-11-21T20:05:53Z
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
Zacks • 2025-11-18T15:33:00Z
How the Narrative Around Alector Is Evolving After the Latest Clinical Setback
Simply Wall St. • 2025-11-07T19:13:52Z
Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates
Zacks • 2025-11-06T23:25:02Z
Alector: Q3 Earnings Snapshot
Associated Press Finance • 2025-11-06T22:29:43ZAlector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab
Insider Monkey • 2025-10-31T09:42:53Z
Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for
Zacks • 2025-10-30T14:00:33Z
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks • 2025-10-29T14:00:06Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $100,558,000 | $97,062,000 | $133,617,000 | $207,085,000 |
| Operating Revenue | $100,558,000 | $97,062,000 | $133,617,000 | $207,085,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $245,555,000 | $248,802,000 | $271,451,000 | $244,445,000 |
| Other Income Expense | $26,076,000 | $26,561,000 | $7,778,000 | $1,031,000 |
| Other Non Operating Income Expenses | $26,076,000 | $26,561,000 | $7,778,000 | $1,031,000 |
| Operating Expense | $245,555,000 | $248,802,000 | $271,451,000 | $244,445,000 |
| General And Administrative Expense | $59,615,000 | $56,687,000 | $61,033,000 | $55,038,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |
| Normalized Income | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |
| Net Income From Continuing And Discontinued Operation | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |
| Total Operating Income As Reported | $-144,997,000 | $-151,740,000 | $-137,834,000 | $-37,360,000 |
| Net Income Common Stockholders | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |
| Net Income | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |
| Net Income Including Noncontrolling Interests | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |
| Net Income Continuous Operations | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |
| Pretax Income | $-118,921,000 | $-125,179,000 | $-130,056,000 | $-36,329,000 |
| Operating Income | $-144,997,000 | $-151,740,000 | $-137,834,000 | $-37,360,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.23 | $-1.56 | $-1.62 | $-0.45 |
| Basic EPS | $-1.23 | $-1.56 | $-1.62 | $-0.45 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-136,156,000 | $-142,892,000 | $-129,362,000 | $-29,045,000 |
| Reconciled Depreciation | $8,841,000 | $8,848,000 | $8,472,000 | $8,315,000 |
| EBITDA (Bullshit earnings) | $-136,156,000 | $-142,892,000 | $-129,362,000 | $-29,045,000 |
| EBIT | $-144,997,000 | $-151,740,000 | $-137,834,000 | $-37,360,000 |
| Diluted Average Shares | $96,588,177 | $83,733,730 | $82,467,587 | $80,416,936 |
| Basic Average Shares | $96,588,177 | $83,733,730 | $82,467,587 | $80,416,936 |
| Diluted NI Availto Com Stockholders | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |
| Tax Provision | $128,000 | $5,212,000 | $3,254,000 | $0 |
| Research And Development | $185,940,000 | $192,115,000 | $210,418,000 | $189,407,000 |
| Selling General And Administration | $59,615,000 | $56,687,000 | $61,033,000 | $55,038,000 |
| Other Gand A | $59,615,000 | $56,687,000 | $61,033,000 | $55,038,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $126,800,000 | $134,158,000 | $214,442,000 | $300,724,000 |
| Total Assets | $468,303,000 | $621,827,000 | $787,648,000 | $814,658,000 |
| Total Non Current Assets | $43,486,000 | $56,020,000 | $61,213,000 | $64,945,000 |
| Other Non Current Assets | $6,390,000 | $8,964,000 | $7,881,000 | $7,046,000 |
| Current Assets | $424,817,000 | $565,807,000 | $726,435,000 | $749,713,000 |
| Other Current Assets | $11,420,000 | $16,946,000 | $10,997,000 | $7,071,000 |
| Cash Cash Equivalents And Short Term Investments | $413,397,000 | $548,861,000 | $712,851,000 | $735,251,000 |
| Cash And Cash Equivalents | $33,021,000 | $74,555,000 | $154,323,000 | $329,152,000 |
| Receivables | - | $0 | $2,587,000 | $7,391,000 |
| Prepaid Assets | - | - | $10,997,000 | $7,071,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $42,519,000 | $38,918,000 | $43,327,000 | $47,601,000 |
| Long Term Debt And Capital Lease Obligation | $33,765,000 | $30,456,000 | $35,268,000 | $39,806,000 |
| Long Term Debt | $9,389,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $8,754,000 | $8,462,000 | $8,059,000 | $7,795,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $341,503,000 | $487,669,000 | $573,206,000 | $513,934,000 |
| Total Non Current Liabilities Net Minority Interest | $216,444,000 | $309,721,000 | $479,397,000 | $374,379,000 |
| Other Non Current Liabilities | $1,234,000 | $1,373,000 | $759,000 | $158,000 |
| Non Current Deferred Liabilities | $172,169,000 | $210,845,000 | $443,370,000 | $334,415,000 |
| Current Liabilities | $125,059,000 | $177,948,000 | $93,809,000 | $139,555,000 |
| Current Deferred Liabilities | $23,663,000 | $82,975,000 | $48,231,000 | $90,803,000 |
| Payables And Accrued Expenses | $25,795,000 | $31,774,000 | $24,761,000 | $29,293,000 |
| Payables | $8,129,000 | $11,478,000 | $4,189,000 | $4,749,000 |
| Other Payable | $5,914,000 | $7,703,000 | - | - |
| Accounts Payable | $2,215,000 | $3,775,000 | $4,189,000 | $4,749,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $126,800,000 | $134,158,000 | $214,442,000 | $300,724,000 |
| Total Equity Gross Minority Interest | $126,800,000 | $134,158,000 | $214,442,000 | $300,724,000 |
| Stockholders Equity | $126,800,000 | $134,158,000 | $214,442,000 | $300,724,000 |
| Gains Losses Not Affecting Retained Earnings | $261,000 | $184,000 | $-4,575,000 | $-943,000 |
| Other Equity Adjustments | $261,000 | $184,000 | $-4,575,000 | $-943,000 |
| Retained Earnings | $-829,127,000 | $-710,078,000 | $-579,687,000 | $-446,377,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $99,085,888 | $84,879,693 | $82,895,718 | $81,986,192 |
| Share Issued | $99,085,888 | $84,879,693 | $82,895,718 | $81,986,192 |
| Tangible Book Value | $126,800,000 | $134,158,000 | $214,442,000 | $300,724,000 |
| Invested Capital | $136,189,000 | $134,158,000 | $214,442,000 | $300,724,000 |
| Working Capital | $299,758,000 | $387,859,000 | $632,626,000 | $610,158,000 |
| Capital Lease Obligations | $33,130,000 | $38,918,000 | $43,327,000 | $47,601,000 |
| Total Capitalization | $136,189,000 | $134,158,000 | $214,442,000 | $300,724,000 |
| Additional Paid In Capital | $955,657,000 | $844,044,000 | $798,696,000 | $748,036,000 |
| Capital Stock | $9,000 | $8,000 | $8,000 | $8,000 |
| Common Stock | $9,000 | $8,000 | $8,000 | $8,000 |
| Non Current Deferred Revenue | $172,169,000 | $210,845,000 | $443,370,000 | $334,415,000 |
| Long Term Capital Lease Obligation | $24,376,000 | $30,456,000 | $35,268,000 | $39,806,000 |
| Long Term Provisions | $9,276,000 | $67,047,000 | - | - |
| Current Deferred Revenue | $23,663,000 | $82,975,000 | $48,231,000 | $90,803,000 |
| Current Capital Lease Obligation | $8,754,000 | $8,462,000 | $8,059,000 | $7,795,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $18,213,000 | $15,297,000 | $12,758,000 | $11,664,000 |
| Current Provisions | $48,634,000 | $39,440,000 | - | - |
| Current Accrued Expenses | $17,666,000 | $20,296,000 | $20,572,000 | $24,544,000 |
| Net PPE | $37,096,000 | $47,056,000 | $53,332,000 | $57,899,000 |
| Accumulated Depreciation | $-32,942,000 | $-28,050,000 | $-22,612,000 | $-17,286,000 |
| Gross PPE | $70,038,000 | $75,106,000 | $75,944,000 | $75,185,000 |
| Leases | $26,357,000 | $26,616,000 | $26,228,000 | $25,949,000 |
| Other Properties | $38,835,000 | $43,688,000 | $44,976,000 | $44,612,000 |
| Machinery Furniture Equipment | $4,846,000 | $4,802,000 | $4,740,000 | $4,624,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $380,376,000 | $474,306,000 | $558,528,000 | $406,099,000 |
| Duefrom Related Parties Current | - | $0 | $2,587,000 | $7,391,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-231,160,000 | $-186,543,000 | $-24,446,000 | $295,304,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-229,905,000 | $-184,162,000 | $-20,329,000 | $298,551,000 |
| Cash Flow From Continuing Operating Activities | $-229,905,000 | $-184,162,000 | $-20,329,000 | $298,551,000 |
| Operating Gains Losses | - | $48,000 | - | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-1,255,000 | $-2,381,000 | $-4,117,000 | $-3,247,000 |
| Investing Cash Flow | $107,131,000 | $101,918,000 | $-159,014,000 | $-49,663,000 |
| Cash Flow From Continuing Investing Activities | $107,131,000 | $101,918,000 | $-159,014,000 | $-49,663,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $71,108,000 | $0 | $0 | $0 |
| Financing Cash Flow | $81,540,000 | $2,550,000 | $4,514,000 | $30,295,000 |
| Cash Flow From Continuing Financing Activities | $81,540,000 | $2,550,000 | $4,514,000 | $30,295,000 |
| Net Common Stock Issuance | $71,108,000 | $0 | $0 | $0 |
| Common Stock Issuance | $71,108,000 | $0 | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Debt | $9,389,000 | $0 | $0 | - |
| End Cash Position | $34,867,000 | $76,101,000 | $155,795,000 | $330,624,000 |
| Beginning Cash Position | $76,101,000 | $155,795,000 | $330,624,000 | $51,441,000 |
| Changes In Cash | $-41,234,000 | $-79,694,000 | $-174,829,000 | $279,183,000 |
| Proceeds From Stock Option Exercised | $1,043,000 | $2,550,000 | $4,514,000 | $30,295,000 |
| Net Issuance Payments Of Debt | $9,389,000 | $0 | $0 | - |
| Net Long Term Debt Issuance | $9,389,000 | $0 | $0 | - |
| Long Term Debt Issuance | $9,389,000 | $0 | $0 | - |
| Net Investment Purchase And Sale | $108,386,000 | $104,299,000 | $-154,897,000 | $-46,416,000 |
| Sale Of Investment | $576,127,000 | $656,028,000 | $402,001,000 | $296,986,000 |
| Purchase Of Investment | $-467,741,000 | $-551,729,000 | $-556,898,000 | $-343,402,000 |
| Net PPE Purchase And Sale | $-1,255,000 | $-2,381,000 | $-4,117,000 | $-3,247,000 |
| Purchase Of PPE | $-1,255,000 | $-2,381,000 | $-4,117,000 | $-3,247,000 |
| Change In Working Capital | $-146,986,000 | $-90,147,000 | $59,526,000 | $283,681,000 |
| Change In Other Working Capital | $-100,558,000 | $-66,782,000 | $66,383,000 | $292,915,000 |
| Change In Other Current Liabilities | $-51,938,000 | $-28,866,000 | $-3,673,000 | $-4,326,000 |
| Change In Other Current Assets | $2,874,000 | $-1,009,000 | $-835,000 | $-2,957,000 |
| Change In Payables And Accrued Expense | $-2,890,000 | $9,872,000 | $-3,227,000 | $4,308,000 |
| Change In Accrued Expense | $340,000 | $2,546,000 | $-2,655,000 | $2,391,000 |
| Change In Payable | $-3,230,000 | $7,326,000 | $-572,000 | $1,917,000 |
| Change In Account Payable | $-1,441,000 | $-377,000 | $-572,000 | $1,917,000 |
| Change In Prepaid Assets | $5,526,000 | $-5,949,000 | $-3,926,000 | $1,132,000 |
| Change In Receivables | $0 | $2,587,000 | $4,804,000 | $-7,391,000 |
| Stock Based Compensation | $39,463,000 | $42,798,000 | $46,146,000 | $40,785,000 |
| Asset Impairment Charge | $2,205,000 | $0 | $0 | $0 |
| Amortization Of Securities | $-14,379,000 | $-15,318,000 | $-1,163,000 | $2,099,000 |
| Depreciation Amortization Depletion | $8,841,000 | $8,848,000 | $8,472,000 | $8,315,000 |
| Depreciation And Amortization | $8,841,000 | $8,848,000 | $8,472,000 | $8,315,000 |
| Depreciation | $8,841,000 | $8,848,000 | $8,472,000 | $8,315,000 |
| Gain Loss On Sale Of PPE | $0 | $48,000 | $0 | $0 |
| Net Income From Continuing Operations | $-119,049,000 | $-130,391,000 | $-133,310,000 | $-36,329,000 |